



# ABSTRACTS

International Conference on  
**CLINICAL PET AND  
MOLECULAR NUCLEAR  
MEDICINE (IPET 2011)**

8–11 November 2011  
Vienna, Austria

International Conference on  
Clinical PET and Molecular Nuclear Medicine  
(IPET 2011)

Vienna, Austria

8-11 November 2011

BOOK OF ABSTRACTS

IAEA-CN-185

## CONTENTS

### CLINICAL PET ONCOLOGY

IAEA-CN-185/104..... Feasibility of biopsy guided by FDG-PET/CT in oncological patients <i>J.J. Cerci, C.C. Pereira Neto, J.V. Vitola</i> IAEA-CN-185/105..... Importance of 18F-FDG PET/CT imaging in patients with lymphoma and residual CT mass after treatment <i>D. Sobic-Saranovic, V. Artiko, M. Todorovic-Tirnanic, V. Obradovic</i> IAEA-CN-185/106..... PET/CT in diagnosis of metastases and recurrences of colorectal carcinomas <i>V. Artiko, D. Sobic-Saranovic, N. Petrovic, V. Obradovic</i> IAEA-CN-185/107..... Pitfalls encountered in 1500 hybrid PET/CT studies <i>V.E. Soroa, J. Arashiro, M.M. Volpacchio, G. Rank, C. Giannone</i> IAEA-CN-185/113..... Results of initial FDG PET/CT staging in recently diagnosed breast cancer patients <i>S. Ozguven, F. Dede, T. Ones, B. Gulluoglu, S. Inanir, T.Y. Erdil, H.T. Turoglu</i> IAEA-CN-185/114..... Morpho-metabolical changes at the operation site in recently mastectomized patients: Impact of staging FDG PET/CT <i>S. Ozguven, F. Dede, T. Ones, B. Gulluoglu, S. Inanir, T.Y. Erdil, H.T. Turoglu</i> IAEA-CN-185/115..... Synchronous metastases in recently diagnosed breast cancer: Role of staging FDG PET/CT <i>S. Ozguven, F. Dede, T. Ones, B. Gulluoglu, S. Inanir, T.Y. Erdil, H.T. Turoglu</i> IAEA-CN-185/117..... The value of FDG-PET/CT imaging in dermatomyositis as a paraneoplastic syndrome in malignancy suspicion <i>M. Aras, T. Ones, F. Dede, F. Novruzov, S.S.C. Omercikoglu, S.Ozguven, S.                  Gungor, S. Inanir, T.Y. Erdil, H.T. Turoglu</i> IAEA-CN-185/121..... Radiological response evaluation of oncolytic virus treatment in patients with advanced cancer <i>A. Koski, K. Kairemo, M. Oksanen, A. Koskela, K. Partanen, A. Hemminki</i> IAEA-CN-185/123..... FDG PET in nephrouinary cancer: Our experience in 60 cases <i>M.J. Jofré, T. Massardo, M.P. Sierralta, J. Canessa, G. Castro, I. Berrocal, R.                  Valdebenito</i> IAEA-CN-185/125..... Significant impact of mid treatment 18-F FDG PET-CT as a prognostic indicator in the management and follow-up of metastatic breast cancer <i>P.S. Choudhury, M. Gupta, A. Chaturvedi, A. Dogra</i> IAEA-CN-185/126..... Usefulness of FDG-PET in the evaluation of sarcomas from diverse origin <i>J. Canessa, T. Massardo, G. Castro, M.J. Jofré, M.P. Sierralta, I. Berrocal, I.                  Gallegos, R. Valdebenito, A. Quenaya</i>	2 3 4 5 8 9 10 11 13 14 16 17
---	--

IAEA-CN-185/247 .....	313
Estimation of the effective radiation dose from Nuclear Medicine procedures in children and from SPECT/CT and PET/CT studies in the general population	
<i>C. Salgado-Garcia, F. Carrera-Magariño, A. Jiménez-Heffernan</i>	
IAEA-CN-185/262.....	314
Evaluation of patient radiation dose during Nuclear Medicine investigations at Dr.M.Djamil Hospital- Padang- Indonesia	
<i>A. Elliyanti, Y. Fitri, P.T. Wahyuni, E.Y. Mailinatri</i>	
IAEA-CN-185/278.....	315
Presentation of a practical tool for shielding calculation in PET/CT facilities	
<i>M.A. Arciniegas Alvarez, H. Alejo Martínez, C.A. de los Reyes</i>	
IAEA-CN-185/308.....	316
Measurement of radiation exposure in relatives of thyroid cancer patients in 131I treatment	
<i>Y.T. Ramírez-Garzón, O. Ávila, L.A. Medina, M.E. Brandan, A.E. Buenfil, I. Gamboa-de Buen, E. Estrada</i>	

**Evaluation of patient radiation dose during Nuclear Medicine investigations at  
Dr.M.Djamil Hospital- Padang- Indonesia**

**A. Elliyanti<sup>a</sup>, Y. Fitri<sup>a</sup>, P.T. Wahyuni<sup>b</sup>, E.Y. Mailinatri<sup>b</sup>**

<sup>a</sup> Dr. M. Djamil Hospital/Faculty of Medicine Andalas University Padang-Indonesia

<sup>b</sup> Faculty of Science Andalas University Padang Indonesia

*Email Address of Main Author: aelliyanti@yahoo.com*

**Background:** Radiation exposure for medical purposes is justified only when it is of benefit to the patient. Radiation dose for medical diagnostics should be low, reasonable and achievable; however, with provision for an adequate and optimum clinical diagnostics. The aim of this study is to determine the radioactivity levels and equivalent radiation dose during nuclear medicine investigations that is within the standardized safe limits at Dr. M. Djamil hospital Padang Indonesia.

**Material and Methods:** Subjects were selected randomly from the patients who were referred to our department for thyroid imaging, bone imaging and renography during the year 2009. They were divided into three groups, based on investigation types and radiopharmaceutical administration:

- 1) Group one: Thyroid imaging, Technetium 99m(99mTc)
- 2) Group two: Bone imaging, Technetium 99m-methylene-diphosphonate (99mTc-MDP).
- 3) Group three: Renography, Technetium 99m-diethylenetriaminepentaacetic acid (99mTc-DTPA).

Dose calibrator (Medisystem-202) and Thermoluminescence dosimetry -100 (TLD -100) were used to measure radioactivity level and equivalent radiation dose respectively. All subjects who were involved in this study had given an informal consent.

**Results:** Thirty four subjects were included in this study with age ranging from 29-65 years of age. 12 subjects participated in group one, 12 in group two and 10 in group three. Group one, two and three received average levels of radioactivity- per test were 4.08 mCi (151 MBq), 14.3 mCi (529 MBq) and 4.46 mCi (165 MBq) respectively. The average of equivalent radiation dose per test for group one, two and three were  $0.31 \pm 0.11$  mSv,  $0.7 \pm 0.31$  mSv,  $0.33 \pm 0.88$  mSv respectively.

**Conclusion:** For patient safety, radioactivity levels and equivalent radiation dose during nuclear medicine investigations at our hospital within international and national guideline of radiation protection, working under standards of radiation protection is mandatory.